Publication for HMGCS1 and MVD

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	HMGCS1	3-hydroxy-3-methylglutaryl-CoA synthase 1	3157			[link]
hsa	MVD	mevalonate diphosphate decarboxylase	4597

Pubmed ID	Priority	Text
31540279	0.98	HMGCS1, HMGCR, FDPS, and MVD, which are tightly regulated by an SREBP2 transcription factor.
	0.97	3-Hydroxy-3-Methylglutaryl-CoA Synthase 1 (HMGCS1), 3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR), farnesyl diphosphate synthase (FDPS), and mevalonate diphosphate decarboxylase (MVD).
	0.85	HMGCS1, mevalonate diphosphate decarboxylase (MVD), and HMGCR in simvastatin-treated SK-HEP-1 cells (Figure 3B).
30206152	0.97	HMGCS1, MVD, MVK, and SQLE), ER/Golgi trafficking (AP1S3 and ASAP2), and cell survival (TNFRSF10D and KLF4) are all induced in ZIKV+ macrophages and, based on previous data, have the potential to increase ZIKV pathogenicity.
	0.65	HMGCS1, MVD, MVK, and SQLE (Fig. 2C).
26535575	0.97	MVD as well as one out of three transcripts for HMGCS1 did not replicate.
24493696	0.96	HMGCS1, HMGCR, MVK, MVD and LDLR, and further reduces the levels of intracellular fatty acid and cholesterol.
	0.94	HMGCS1, HMGCR, MVK, MVD and LDLR and two chaperones, INSIG-1 and SCAP in LNCaP and C4-2B cells examined by qRT-PCR.
	0.90	HMGCS1, HMGCR, MVK and MVD and two chaperones, INSIG-1 and SCAP compared to the control group.
	0.73	HMGCS1, HMGCR, MVK, MVD and LDLR for cholesterogenesis, two chaperones, INSIG1 and SCAP.
31561416	0.96	HMGCS1), HMG-CoA reductase (HMGCR), farnesyl diphosphate synthase (FDPS), and mevalonate diphosphate decarboxylase (MVD), for de novo cholesterol synthesis.
	0.94	HMGCS1, HMGCR, MVD, and FDPS, in order to increase intracellular cholesterol levels.
	0.53	HMGCS1, HMGCR, MVD, FDPS, and SREBP2), fatty acid synthesis (SREBP1a and SREBP1c), and cholesterol uptake (LDL-R) in UA-treated SK-HEP-1 cells, and this UA-induced gene expression was similar to that observed with simvastatin treatment (Figure 2A).
26202976	0.96	HMGCS1, HMGCS2, HMGCR, MVK, PMVK, MVD, IDI1, IDI2, FDPS, GGPS1) were subject to mutation screening.
29927962	0.96	HMGCS1, INSIG1, CYP51A1, PCSK9, DHCR24, HMGCR, LSS, ACAT2, SQLE, NSDHL, EBP, FAP, MVD, DHCR7, APOL1, LDLR, APOL3, FDFT1 and ABCG1).
32033570	0.95	HMGCR, 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1), mevalonate diphosphate decarboxylase (MVD), and SQLE, thereby facilitating the cholesterol synthesis and changing the invadopodia cell membrane fluidity (Fig. 7b).
	0.87	HMGCS1, HMGCR, MVD, SQLE were all deregulated by HADHA.
31098406	0.94	HMGCS1), metabolic pathways (MVD and BAAT), cell cycle signaling pathway (MCM4 and MCM5), and DNA replication pathway (MCM2 and POLE) (n = 3).
31685796	0.94	Hmgcs1, Hmgcr, Mvk, Mvd, and Idi1, appeared to be significantly enriched (P < 0.05, FDR < 0.25) in ASPP2-depleted HCC-LM3 cells (Fig. 1b).
26883200	0.92	HMGCS1, HMGCR, MVD and LDLR in LNCaP cells, while knockdown of SREBP-2 resulted in decreases of genes above in CWR22Rv1 cells (Supplementary Figures S11A and S11B).
	0.90	HMGCS1), 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR), mevalonate kinase (MVK), mevalomate 5-pyrophosphate decarboxylase (MVD) and low-density lipoprotein receptor (LDLR) in PCa cells with genetically manipulated SREBP-2.
27458152	0.92	HMGCS1, MVD and INSIG1) were verified in four cell lines with statistically significant higher average fold increases observed for three of these genes in the less sensitive cells (MCF7 and T47D) relative to the sensitive cells (SKBR3 and MDA-MB-231) after 48 hours exposure to atorvastatin (Figure 1B).
30321984	0.92	HMGCS1, HMGCR, mevalonate diphosphate decarboxylase (MVD), FDPS, and 7-dehydrocholesterol reductase (DHCR7) expression, by simvastatin was significantly decreased by 20 muM emodin in SK-HEP-1 (Figure 4B) and HepG2 (Figure 4C) cells.
27654507	0.86	HMGCS1, MVK, MVD, IDI1, and FDPS) decreased in abundance in the ARID1A knockout (Table I).
16168081	0.82	mevalonate decarboxylase (MVD), hydroxy-3-methylglutaryl-coenzyme A synthase 1 (HMGCS1), and HMG-coenzyme A reductase (HMGCR), the rate-limiting enzyme in cholesterol synthesis and the target of the 'statin' class of drugs for patients with dyslipidemia.
26512780	0.78	3-hydroxy-3-methyl-glutaryl-CoA synthase 1 (HMGCS1), HMGCR, mevalonate kinase (MVK), mevalonate 5-pyrophosphate decarboxylase (MVD) and low-density lipoprotein receptor (LDLR) for cholesterogenesis; and two chaperones, insulin-induced gene 1 (INSIG1) and SREBP cleavage activating protein (SCAP) in PC-3 EV, PC-3 R248W and DU145 cells.
25672394	0.76	HMGCS1, MVD, IDI1, FDPS, FDFT1, CYP51, SC4MOL, NSDHL were simultaneously upregulated.
26938778	0.67	HMGCS1 (Entrez Gene: 208715), HMGCR (Entrez Gene: 15357), MVD (Entrez Gene: 192156), SQLE (Entrez Gene: 20775), and SREBF2 (Entrez Gene: 20788) in CH25H -/- cells treated with interferon gamma (IFN-gamma) (UniProt: P01580).
31181660	0.64	HMGCS1), 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), Mevalonate kinases (MVK), Phosphomevalonate Kinase (PMVK), Mevalonate Diphosphate Decarboxylase (MVD), 7-Dehydrocholesterol reductase (DHCR7)) (Figure 1c and Figure S1d).
31253778	0.62	Mvd, and Hmgcs1), respectively (Fig. 2c and Supplementary Fig. 4b).
22684502	0.53	Hmgcs1, Mvd, Idi1, Fdft1, Tm7sf2, Ebp, Nsdhl, Sc5d and Dhcr24) (Figure 7A).
31604910	0.51	HMGCS1, MVK, MVD, and SQLE was also significantly downregulated by XY018 or its combination with statin (Fig. 7c, Supplementary Fig. 7a).